scholarly journals Stroke Prevention in Older Adults

Stroke ◽  
2020 ◽  
Vol 51 (12) ◽  
pp. 3770-3777
Author(s):  
J. David Spence ◽  
M. Reza Azarpazhooh ◽  
Susanna C. Larsson ◽  
Chrysi Bogiatzi ◽  
Graeme J. Hankey

The risks of stroke and dementia increase steeply with age, and both are preventable. At present, the best way to preserve cognitive function is to prevent stroke. Therapeutic nihilism based on age is common and unwarranted. We address recent advances in stroke prevention that could contribute greatly to prevention of stroke and dementia at a time when the aging of the population threatens to markedly increase the incidence of both. Issues discussed: (1) old patients benefit even more from lipid-lowering therapy than do younger patients; (2) patients with stiff arteries are at risk from a target systolic blood pressure <120 mm Hg; (3) the interaction of the intestinal microbiome, age, and renal function has important dietary implications for older adults; (4) anticoagulation with direct-acting oral anticoagulants should be prescribed more to old patients with atrial fibrillation; (5) B vitamins to lower homocysteine prevent stroke; and (6) most old patients in whom intervention is warranted for carotid stenosis would benefit more from endarterectomy than from stenting. An 80-year-old person has much to lose from a stroke and should not have effective therapy withheld on account of age. Lipid-lowering therapy, a more plant-based diet, appropriate anticoagulation or antiplatelet therapy, appropriate blood pressure control, B vitamins to lower homocysteine, and judicious intervention for carotid stenosis could do much to reduce the growing burden of stroke and dementia.

2021 ◽  
pp. 1-14
Author(s):  
M. Reza Azarpazhooh ◽  
Chrysi Bogiatzi ◽  
J. David Spence

Combining available therapies has the potential to reduce the risk of stroke by 80% or more. A comprehensive review of all aspects of stroke prevention would be very lengthy; in this narrative review, we focus on some aspects of stroke prevention that are little-known and/or neglected. These include the following: (1) implementation of a Mediterranean diet; (2) B vitamins to lower homocysteine; (3) coordinated approaches to smoking cessation; (4) intensive lipid-lowering therapy; (5) lipid lowering in the elderly; (6) physiologically individualized therapy for hypertension based on renin/aldosterone phenotyping; (7) avoiding excessive blood pressure reduction in patients with stiff arteries; (8) treatment of insulin resistance with pioglitazone in stroke patients with prediabetes and diabetes; (9) impaired activation of clopidogrel in patients with variants of CYP2C19; (10) aspirin pseudoresistance due to enteric coating; (11) rationale for anticoagulation in patients with embolic stroke of unknown source; (12) pharmacologic properties of direct-acting oral anticoagulants that should be considered when choosing among them; (13) the identification of which patients with asymptomatic carotid stenosis are at a high enough risk to benefit from carotid endarterectomy or stenting; and (14) the importance of age in choosing between endarterectomy and stenting. Stroke prevention could be improved by better recognition of these issues and by implementation of the principles derived from them.


2016 ◽  
Vol 204 (8) ◽  
pp. 320-320 ◽  
Author(s):  
Emily Banks ◽  
Simon R Crouch ◽  
Rosemary J Korda ◽  
Bill Stavreski ◽  
Karen Page ◽  
...  

2008 ◽  
Vol 35 (6) ◽  
pp. 661-668 ◽  
Author(s):  
N.P.E. Kadoglou ◽  
T. Gerasimidis ◽  
A. Moumtzouoglou ◽  
A. Kapelouzou ◽  
N. Sailer ◽  
...  

2018 ◽  
Vol 36 ◽  
pp. e144-e145
Author(s):  
Li Xing Chao ◽  
Ying Xin Zhao ◽  
Fang Hong Lu ◽  
Guang Juan Wang ◽  
Hua Zhang ◽  
...  

Heart ◽  
2019 ◽  
Vol 106 (4) ◽  
pp. 261-266 ◽  
Author(s):  
Emma EF Kleipool ◽  
Johannes AN Dorresteijn ◽  
Yvo M Smulders ◽  
Frank LJ Visseren ◽  
Mike JL Peters ◽  
...  

Due to an increasing number of older adults with (risk factors for) cardiovascular disease (CVD), the sum of older adults eligible for lipid-lowering drugs will increase. This has risen questions about benefits and harms of lipid-lowering therapy in older adults with a varying number of (cardiovascular) comorbidities and functional status. The heterogeneity in physical and functional health increases with age, leading to a much wider variety in cardiovascular risk and life expectancy than in younger adults. We suggest treatment decisions on hypercholesterolaemia in adults aged ≥75 years should shift from a strictly 10-year cardiovascular risk-driven approach to a patient-centred and lifetime benefit-based approach. With this, estimated 10-year risk of CVD should be placed into the perspective of life expectancy. Moreover, frailty and safety concerns must be taken into account for a risk–benefit discussion between clinician and patient. Based on the Dutch addendum ‘Cardiovascular Risk Management in (frail) older adults’, our approach offers more detailed information on when not to initiate or deprescribe therapy than standard guidelines. Instead of using traditional risk estimating tools which tend to overestimate risk of CVD in older adults, use a competing risk adjusted, older adults-specific risk score (available at https://u-prevent.com). By filling in a patient’s (cardiovascular) health profile (eg, cholesterol, renal function), the tool estimates risk of CVD and models the effect of medication in terms of absolute risk reduction for an individual patient. Using this tool can guide doctors and patients in making shared decisions on initiating, continuing or deprescribing lipid-lowering therapy.


2004 ◽  
Vol 4 (2) ◽  
pp. 233-239 ◽  
Author(s):  
Bartlomiej Piechowski-Jozwiak ◽  
Julien Bogousslavsky

Sign in / Sign up

Export Citation Format

Share Document